Hayfin Expects Private-Debt M&A; BI on Ozempic Risks

Private-debt firms are set to consolidate as larger companies dominate deal flow, according to Marc Chowrimootoo, portfolio manager at Hayfin Capital Management. “We’re seeing a concentration within fewer hands,” Chowrimootoo tells Bloomberg News’ Lisa Lee and James Crombie and Bloomberg Intelligence’s Julie Hung in the latest Credit Edge podcast. “That trend is going to continue.” He identifies debt refinancing as the big opportunity for private lenders in 2024. Hayfin likes the health-care and software sectors, while avoiding smaller borrowers that are struggling with higher rates. In addition, BI’s Hung weighs the impact on food and drink companies of weight-loss drugs like Ozempic. See omnystudio.com/listener for privacy information.